Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
Regeneron Pharmaceuticals (NASDAQ: REGN) has scheduled the release of its first quarter 2025 financial and operating results for Tuesday, April 29, 2025, before U.S. market opening. The company will host a conference call and webcast at 8:30 AM Eastern Time on the same day.
Investors can access the conference call through a webcast on Regeneron's investor relations website. Telephone participants must pre-register to receive dial-in details and access credentials. A replay and transcript will be available on the company's website for a minimum of 30 days following the call.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha programmato la pubblicazione dei suoi risultati finanziari e operativi del primo trimestre 2025 per martedì 29 aprile 2025, prima dell'apertura del mercato statunitense. L'azienda ospiterà una teleconferenza e una webcast alle 8:30 AM ora orientale nello stesso giorno.
Gli investitori possono accedere alla teleconferenza tramite una webcast sul sito web delle relazioni con gli investitori di Regeneron. I partecipanti telefonici devono preregistrarsi per ricevere i dettagli per la chiamata e le credenziali di accesso. Una registrazione e una trascrizione saranno disponibili sul sito web dell'azienda per un minimo di 30 giorni dopo la chiamata.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha programado la publicación de sus resultados financieros y operativos del primer trimestre de 2025 para el martes 29 de abril de 2025, antes de la apertura del mercado estadounidense. La compañía llevará a cabo una conferencia telefónica y una transmisión en vivo a las 8:30 AM, hora del Este, el mismo día.
Los inversores pueden acceder a la conferencia telefónica a través de una transmisión en vivo en el sitio web de relaciones con los inversores de Regeneron. Los participantes por teléfono deben registrarse previamente para recibir los detalles de acceso y las credenciales. Una grabación y una transcripción estarán disponibles en el sitio web de la compañía durante un mínimo de 30 días después de la llamada.
레제너론 제약 (NASDAQ: REGN)은 2025년 1분기 재무 및 운영 결과를 2025년 4월 29일 화요일 미국 시장 개장 전에 발표할 예정입니다. 회사는 같은 날 오전 8시 30분 동부 표준시(EST)에 컨퍼런스 콜과 웹캐스트를 진행합니다.
투자자는 레제너온의 투자자 관계 웹사이트를 통해 컨퍼런스 콜에 접속할 수 있습니다. 전화 참가자는 다이얼인 세부정보와 액세스 자격을 받기 위해 사전 등록해야 합니다. 통화 후 최소 30일 동안 회사 웹사이트에서 재생 및 전사가 제공됩니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a programmé la publication de ses résultats financiers et opérationnels du premier trimestre 2025 pour le mardi 29 avril 2025, avant l'ouverture du marché américain. L'entreprise organisera une conférence téléphonique et un webinaire le même jour à 8h30, heure de l'Est.
Les investisseurs peuvent accéder à la conférence téléphonique via un webinaire sur le site web des relations investisseurs de Regeneron. Les participants par téléphone doivent s'inscrire à l'avance pour recevoir les détails de connexion et les informations d'accès. Un enregistrement et une transcription seront disponibles sur le site de l'entreprise pendant un minimum de 30 jours après l'appel.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat die Veröffentlichung seiner Finanz- und Betriebsergebnisse für das erste Quartal 2025 für Dienstag, den 29. April 2025, vor der Eröffnung des US-Marktes angesetzt. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten.
Investoren können auf die Telefonkonferenz über einen Webcast auf der Investor-Relations-Website von Regeneron zugreifen. Telefonteilnehmer müssen sich im Voraus registrieren, um die Einwahldaten und Zugangsdaten zu erhalten. Eine Aufzeichnung und ein Transkript werden für mindestens 30 Tage nach dem Anruf auf der Website des Unternehmens verfügbar sein.
- None.
- None.
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
| Contact Information: | |
| Investor Relations | Corporate Communications |
| Ryan Crowe | Christina Chan |
| 914.847.8790 | 914.847.8827 |
| ryan.crowe@regeneron.com | christina.chan@regeneron.com |
FAQ
When will Regeneron (REGN) release Q1 2025 earnings?
What time is Regeneron's (REGN) Q1 2025 earnings call?
How can investors access Regeneron's (REGN) Q1 2025 earnings call?
How long will Regeneron's (REGN) Q1 2025 earnings call replay be available?
